Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center
Background: Systemic immunosuppression characterizing cancer patients represents a concern regarding the efficacy of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, and real-world evidence is needed to define the efficacy and the dynamics of humoral immune response to...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-07-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359221108687 |
| _version_ | 1811311947507826688 |
|---|---|
| author | Giovanni Fucà Mara Lecchi Chiara Maura Ciniselli Arianna Ottini Andrea Spagnoletti Laura Mazzeo Daniele Morelli Paola Frati Martina Stroscia Elisabella Ebrahem Elisa Sottotetti Giulia Galli Maria Grazia D’Elia Riccardo Lobefaro Monika Ducceschi Lorenza Di Guardo Sherrie Bhoori Salvatore Provenzano Marco Platania Monica Niger Elena Colombo Federico Nichetti Matteo Duca Licia Rivoltini Roberta Mortarini Paolo Baili Giovanni Apolone Filippo de Braud Paolo Verderio Silvia Damian |
| author_facet | Giovanni Fucà Mara Lecchi Chiara Maura Ciniselli Arianna Ottini Andrea Spagnoletti Laura Mazzeo Daniele Morelli Paola Frati Martina Stroscia Elisabella Ebrahem Elisa Sottotetti Giulia Galli Maria Grazia D’Elia Riccardo Lobefaro Monika Ducceschi Lorenza Di Guardo Sherrie Bhoori Salvatore Provenzano Marco Platania Monica Niger Elena Colombo Federico Nichetti Matteo Duca Licia Rivoltini Roberta Mortarini Paolo Baili Giovanni Apolone Filippo de Braud Paolo Verderio Silvia Damian |
| author_sort | Giovanni Fucà |
| collection | DOAJ |
| description | Background: Systemic immunosuppression characterizing cancer patients represents a concern regarding the efficacy of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, and real-world evidence is needed to define the efficacy and the dynamics of humoral immune response to mRNA-based anti-SARS-CoV-2 vaccines. Methods: We conducted an observational study that included patients with solid tumors who were candidates for mRNA anti-SARS-CoV-2 vaccination at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. The primary objective was to monitor the immunologic response to the mRNA anti-SARS-CoV-2 vaccination in terms of anti-spike antibody levels. All the patients received two doses of the mRNA-1273 vaccine or the BNT162b2 vaccine. Healthcare workers served as a control group of healthy subjects. Results: Among the 243 patients included in the present analysis, 208 (85.60%) and 238 (97.94%) resulted seroconverted after the first and the second dose of vaccine, respectively. Only five patients (2.06%) had a negative titer after the second dose. No significant differences in the rate of seroconversion after two vaccine doses were observed in patients as compared with the control group of healthy subjects. Age and anticancer treatment class had an independent impact on the antibody titer after the second dose of vaccination. In a subgroup of 171 patients with available data about the third timepoint, patients receiving immunotherapy with immune checkpoint inhibitors seem to have a higher peak of antibodies soon after the second dose (3 weeks after), but a more pronounced decrease at a late timepoint (3 months after). Conclusions: The systemic immunosuppression characterizing cancer patients did not seem to dramatically affect the humoral response to anti-SARS-CoV-2 mRNA vaccines in our population of patients with solid tumors. Further investigation is needed to dissect the interplay between immunotherapy and longitudinal dynamics of humoral response to mRNA vaccines, as well as to analyze the cellular response to mRNA vaccines in cancer patients. |
| first_indexed | 2024-04-13T10:27:54Z |
| format | Article |
| id | doaj.art-f05777205f62491487f8dae093b20afa |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-04-13T10:27:54Z |
| publishDate | 2022-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-f05777205f62491487f8dae093b20afa2022-12-22T02:50:16ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592022-07-011410.1177/17588359221108687Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer centerGiovanni FucàMara LecchiChiara Maura CiniselliArianna OttiniAndrea SpagnolettiLaura MazzeoDaniele MorelliPaola FratiMartina StrosciaElisabella EbrahemElisa SottotettiGiulia GalliMaria Grazia D’EliaRiccardo LobefaroMonika DucceschiLorenza Di GuardoSherrie BhooriSalvatore ProvenzanoMarco PlataniaMonica NigerElena ColomboFederico NichettiMatteo DucaLicia RivoltiniRoberta MortariniPaolo BailiGiovanni ApoloneFilippo de BraudPaolo VerderioSilvia DamianBackground: Systemic immunosuppression characterizing cancer patients represents a concern regarding the efficacy of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, and real-world evidence is needed to define the efficacy and the dynamics of humoral immune response to mRNA-based anti-SARS-CoV-2 vaccines. Methods: We conducted an observational study that included patients with solid tumors who were candidates for mRNA anti-SARS-CoV-2 vaccination at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. The primary objective was to monitor the immunologic response to the mRNA anti-SARS-CoV-2 vaccination in terms of anti-spike antibody levels. All the patients received two doses of the mRNA-1273 vaccine or the BNT162b2 vaccine. Healthcare workers served as a control group of healthy subjects. Results: Among the 243 patients included in the present analysis, 208 (85.60%) and 238 (97.94%) resulted seroconverted after the first and the second dose of vaccine, respectively. Only five patients (2.06%) had a negative titer after the second dose. No significant differences in the rate of seroconversion after two vaccine doses were observed in patients as compared with the control group of healthy subjects. Age and anticancer treatment class had an independent impact on the antibody titer after the second dose of vaccination. In a subgroup of 171 patients with available data about the third timepoint, patients receiving immunotherapy with immune checkpoint inhibitors seem to have a higher peak of antibodies soon after the second dose (3 weeks after), but a more pronounced decrease at a late timepoint (3 months after). Conclusions: The systemic immunosuppression characterizing cancer patients did not seem to dramatically affect the humoral response to anti-SARS-CoV-2 mRNA vaccines in our population of patients with solid tumors. Further investigation is needed to dissect the interplay between immunotherapy and longitudinal dynamics of humoral response to mRNA vaccines, as well as to analyze the cellular response to mRNA vaccines in cancer patients.https://doi.org/10.1177/17588359221108687 |
| spellingShingle | Giovanni Fucà Mara Lecchi Chiara Maura Ciniselli Arianna Ottini Andrea Spagnoletti Laura Mazzeo Daniele Morelli Paola Frati Martina Stroscia Elisabella Ebrahem Elisa Sottotetti Giulia Galli Maria Grazia D’Elia Riccardo Lobefaro Monika Ducceschi Lorenza Di Guardo Sherrie Bhoori Salvatore Provenzano Marco Platania Monica Niger Elena Colombo Federico Nichetti Matteo Duca Licia Rivoltini Roberta Mortarini Paolo Baili Giovanni Apolone Filippo de Braud Paolo Verderio Silvia Damian Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center Therapeutic Advances in Medical Oncology |
| title | Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center |
| title_full | Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center |
| title_fullStr | Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center |
| title_full_unstemmed | Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center |
| title_short | Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center |
| title_sort | efficacy of mrna anti sars cov 2 vaccination and dynamics of humoral immune response in patients with solid tumors results from the institutional registry of an italian tertiary cancer center |
| url | https://doi.org/10.1177/17588359221108687 |
| work_keys_str_mv | AT giovannifuca efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT maralecchi efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT chiaramauraciniselli efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT ariannaottini efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT andreaspagnoletti efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT lauramazzeo efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT danielemorelli efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT paolafrati efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT martinastroscia efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT elisabellaebrahem efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT elisasottotetti efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT giuliagalli efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT mariagraziadelia efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT riccardolobefaro efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT monikaducceschi efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT lorenzadiguardo efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT sherriebhoori efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT salvatoreprovenzano efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT marcoplatania efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT monicaniger efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT elenacolombo efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT federiconichetti efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT matteoduca efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT liciarivoltini efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT robertamortarini efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT paolobaili efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT giovanniapolone efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT filippodebraud efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT paoloverderio efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter AT silviadamian efficacyofmrnaantisarscov2vaccinationanddynamicsofhumoralimmuneresponseinpatientswithsolidtumorsresultsfromtheinstitutionalregistryofanitaliantertiarycancercenter |